01834nas a2200193   4500008004100000022001400041245013200055210006900187260000900256300001400265490000700279520110900286100002401395700002501419700002501444700002001469700002401489856012701513       2020                        eng d  a1466-803300aDrug-drug cocrystals of anticancer drugs erlotinib-furosemide and gefitinib-mefenamic acid for alternative multi-drug treatment0 aDrugdrug cocrystals of anticancer drugs erlotinibfurosemide and   cOCT   a6137-61510 v223 a<p>Drug-drug cocrystals of anticancer drugs erlotinib and gefitinib with furosemide and mefenamic acid, respectively, have been synthesized. The 1:1 erlotinib-furosemide cocrystal crystallizes in the monoclinic centrosymmetric P2(1)/n space group containing one molecule of each component in the asymmetric unit. In contrast the 1:1 gefitinib-mefenamic acid cocrystal hydrate belongs to the monoclinic centrosymmetric P2(1)/c space group comprising one molecule of both drugs along with one water molecule in the asymmetric unit. The solubility and dissolution rate study revealed higher solubility for BCS class II drugs, furosemide, and mefenamic acid, while the solubility and dissolution rate of erlotinib showed a significant reduction in the cocrystal salt. Conversely, the solubility of gefitinib didn't reveal a substantial decrease; however, the dissolution rate has been reduced in the cocrystal hydrate. Further, an attempt has been made to correlate the crystal structures of the erlotinib-furosemide and gefitinib-mefenamic acid cocrystals with their solubilities and dissolution rate.</p>
1 aGeorge, Christy, P.1 aThorat, Shridhar, H.1 aShaligram, Parth, S.1 aSuresha, P., R.1 aGonnade, Rajesh, G.  uhttps://library.ncl.res.in/content/drug-drug-cocrystals-anticancer-drugs-erlotinib-furosemide-and-gefitinib-mefenamic-acid02661nas a2200253   4500008004100000022001400041245017300055210006900228260000800297300001100305490000800316520177800324653001502102653001202117653002502129653001202154100001702166700001702183700002002200700001902220700002102239700002202260856012502282       2021                        eng d  a0927-776500aDesign and synthesis of a new topical agent for halting blood loss rapidly: a multimodal chitosan-gelatin xerogel composite loaded with silica nanoparticles and calcium0 aDesign and synthesis of a new topical agent for halting blood lo  cFEB  a1114540 v1983 a<p>Uncontrolled hemorrhage often causes death during traumatic injuries and halting exsanguination topically is a challenge. Here, an efficient multimodal topical hemostat was developed by (i) ionically crosslinking chitosan and gelatin with sodium tripolyphosphate for (ii) fabricating a robust, highly porous xerogel by lyophilization having 86.7 % porosity, by micro-CT and large pores similar to 30 mu m by SEM (iii) incorporating 0.5 mg synthesized silica nanoparticles (SiNPs, 120 nm size, -22 mV charge) and 2.5 mM calcium in xemgel composite that was confirmed by FTIR analysis with peaks at 3372, 986 and 788 cm(-1), respectively. XPS analysis displayed the presence of SiNPs (Si2p peak for silicon) and calcium (Ca2p1, Ca2p3 transition peaks) in the composite. Interestingly, in silico percolation simulation for composite revealed interlinked 800 mu m long-conduits predicting excellent absorption capacity and validated experimentally (640 % of composite dry weight). The composite achieved &gt;16-fold improved blood clotting in vitro than commercial Celox and Gauze through multimodal interaction of its components with RBCs and platelets. The composite displayed good platelet activation and thrombin generation activities. It displayed high compressive strength (2.45 MPa) and withstood pressure during application. Moreover, xerogel composite showed high biocompatibility. In vivo application of xerogel composite to lethal femoral artery injury in rats achieved hemostasis (2.5 min) significantly faster than commercial Celox (3.3 min) and Gauze (4.6 min) and was easily removed from the wound. The gamma irradiated composite was stable till 1.5 yr. Therefore, the xerogel composite has potential for application as a rapid topical hemostatic agent.</p>
10aHemostatic10aPolymer10asilica nanoparticles10aXerogel1 aPatil, Gokul1 aTorris, Arun1 aSuresha, P., R.1 aJadhav, Sachin1 aBadiger, Manohar1 aGhormade, Vandana  uhttps://library.ncl.res.in/content/design-and-synthesis-new-topical-agent-halting-blood-loss-rapidly-multimodal-chitosan